Bio-Rad Laboratories, Inc. Class A Common Stock vs National Beverage Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while National Beverage Corp. trades at $30.89 (market cap $2.89B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.8× National Beverage Corp.'s market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| BIO | FIZZ | |
|---|---|---|
Market Cap | $8.04B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $47.69 |
52-Week Low | $241.71 | $30.92 |
Enterprise Value | $7.85B | $2.60B |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FIZZ (National Beverage Corp.) trades at $31.13, down 7.95% over 24 hours, with a bearish technical signal and recent earnings misses in three of the last four quarters. The company reported $1.2B revenue and $186.82M net income for 2025, with strong profitability margins but a negative net cash flow of $133.21M. A special dividend of $3.25 per share was declared, payable July 30, 2026, providing a near-term catalyst.
Outlook is mixed: strong fundamentals and dividend support value, but technical weakness and earnings misses signal caution. Risks include competitive pressures and consumer spending trends. Analyst consensus is cautious with 50% sell ratings. The stock presents a high-risk opportunity for dividend-focused investors amid volatility.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →